Newsletter Subject

FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent'

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Thu, Nov 16, 2023 11:53 PM

Email Preheader Text

Daily Headlines Thursday, November 16, 2023 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLI

[MEDPAGE TODAY]( Daily Headlines Thursday, November 16, 2023 Today's Top Stories for {NAME} [ONCOLOGY/HEMATOLOGY]( [FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent']( [SPECIAL REPORTS]( [What to Know About Lead Toxicity and Kids' Applesauce]( [MEETING COVERAGE]( [Here's Why People Think They Developed Food Allergies]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Employing Collaborative Care Strategies for the Management of Pediatric Patients With Hodgkin Lymphoma]( [RADIOLOGY]( [ASTRO Updates Guidelines on Partial Breast Irradiation for Early Invasive Cancer]( [POP MEDICINE]( [Residents, Blink Twice for Help; Strangest GI Bugs; Playlists for the OR]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [INFECTIOUS DISEASE]( [First At-Home Test for Chlamydia and Gonorrhea Authorized by FDA]( CME SPOTLIGHT [Applying the Latest Clinical Evidence to Treatment Plans for Pediatric Patients With Hodgkin Lymphoma]( [POP MEDICINE]( [Are Selfie-Related Deaths a Public Health Issue?]( [SPECIAL REPORTS]( [Medical Board Reprimands Doctor Who Worked While COVID-Positive]( [CLINICAL CHALLENGES]( [Clinical Challenges: What Physicians Prescribe Affects Dry Eye Disease]( CME SPOTLIGHT [Uncovering the Under-Diagnosed in MDS: The MDS Diagnostic Accelerator Hub]( [MEETING COVERAGE]( [Calls to Support Stark Law Reforms Blocked by AMA Delegates]( [SPECIAL REPORTS]( [Nurse Fatally Stabbed; Doctor Sues Mayo; Maya Kowalski's Criminal Complaint]( [OPINION]( [A Wake-Up Call for Physicians: Our Scope of Practice Includes the Climate]( CME SPOTLIGHT [Expanding Evaluation and Referral of Anemia in Primary Care Settings to Diagnose Underlying Myelodysplastic Syndromes]( [ONCOLOGY/HEMATOLOGY]( [FDA OKs New Option for Advanced ROS1-Positive Lung Cancer]( [MEETING COVERAGE]( [Another Long-Acting Steroid Shot Impresses in Knee OA]( [PULMONOLOGY]( [Unclear if Chronic Cough Drug Has Meaningful Benefit, FDA Reviewers Say]( CME SPOTLIGHT [Examining B7-H3: An Emerging Therapeutic Target for Solid Tumors]( [ASCO READING ROOM]( [Rodabe Amaria, MD, on the Shifting Paradigm for Neoadjuvant Immunotherapy for Stage III Melanoma]( [ASCO READING ROOM]( [Collaborative Discussions and Treatment Planning Crucial for Neoadjuvant Immunotherapy in Melanoma]( [MEETING COVERAGE]( [Novel Gout Drug Aces Mid-Stage Tests]( CME SPOTLIGHT [Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome]( [MEDICAL JOURNEYS]( [Choosing Among the Many Treatment Options for Prostate Cancer]( [MEDICAL JOURNEYS]( [For Your Patients: What Are Your Options for Prostate Cancer Treatment?]( # Weekly Survey [Drop Medicare Patients If Pay Cut Goes Through?]( Physicians will face a [3.4% cut in payments]( for their Medicare patients in 2024 unless Congress intervenes[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2023-11-16&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.